Novo CEO expects patients to stay on Wegovy longer than older weight
loss drugs
Send a link to a friend
[January 10, 2024]
(Reuters) - Novo Nordisk's CEO said on Tuesday he expects
patients will stick with the company's popular obesity drug Wegovy for
far longer than those using older treatments.
"We know from all medical interventions, stay time is not like a 100%...
but I think we will see a significantly higher stay time than what we
have seen so far on obesity treatment," said Lars Fruergaard Jorgensen
at the JPMorgan Healthcare conference in San Francisco.
The Danish drugmaker's chief executive said the effects patients see
after being on Wegovy would be an incentive for them to continue,
although it may be "too early to tell." In a pivotal clinical trial,
patients lost an average of 15% of their weight on Wegovy.
Forty percent of patients who filled a prescription for Wegovy in 2021
or 2022 were still taking it a year later, more than three times the
rate of adherence with older medicines, according to an analysis of
medical records and insurance claims data published last month.
Novo and U.S. drugmaker Eli Lilly currently dominate the market for new
weight loss drugs that analysts have forecast could be worth $100
billion by the end of the decade. Several companies are scrambling to
get in on that expected windfall.
![](http://archives.lincolndailynews.com/2024/Jan/10/images/ads/current/charrons_bch_2022.png)
Jorgensen said on Tuesday that Novo was currently catering to 14 million
diabetes and obesity patients globally, and that it "welcomes
competition" in the market for obesity treatments.
[to top of second column]
|
![](../images/011024PIX/health32.jpg)
Novo Nordisk Chief Executive Lars Fruergaard Jorgensen speaks to
reporters at the company's headquarters in Copenhagen, Denmark,
February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo
![](http://archives.lincolndailynews.com/2024/Jan/10/images/ads/current/businessdirectory_dailycover_2023.png) Wegovy, which has the same active
ingredient as the company's type 2 diabetes drug Ozempic, was
approved for obesity in June 2021 and has proved to be wildly
popular.
A rival drug from Lilly, Zepbound, was approved in November. Both
injectable drugs belong to a class of medicines called GLP-1
agonists originally developed for diabetes. In addition to
controlling blood sugar, they suppress appetite and promote a
feeling of fullness.
Jorgensen said there was space in the obesity market for both
injectable and oral treatments.
The company's once-daily weight-loss pill has showed similar
efficacy and safety to Wegovy in a late-stage trial.
(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru;
Editing by Bill Berkrot)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |